Clinical trial
An Open Label, Parallel Group Comparison Study To Evaluate the Safety Tolerability, and Pharmacokinetics of UHE-103 Cream Versus Naftin Cream in Subjects With Tinea Cruris and/or Tinea Pedis Under Maximal Use Conditions
NCT05363449 is registered in ClinicalTrials.gov with Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Parallel Group Comparison Study To Evaluate the Safety Tolerability, and Pharmacokinetics of UHE-103 Cream Versus Naftin Cream in Subjects With Tinea Cruris and/or Tinea Pedis Under Maximal Use Conditions
- Lead sponsor
- Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 17, 2022
- Completion date
- November 14, 2023
- Enrollment
- 42 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.